Back to Search Start Over

TRAMETINIB EXPERIENCE IN A BRAF P.N 486 _P490DEL MUTATION POSITIVE LANGERHANS CELL HISTIOCYTOSIS

Authors :
Sevim Gencel Karaaslan
Gül Hatice Erkol Tuncer
Melek Yaman Ortakoylu
Sonay Incesoy Ozdemir
Handan Dincaslan
Nurdan Tacyildiz
Ömer Suat Fitoz
Koray Ceyhan
Isinsu Kuzu
Emel Cabi Unal
Source :
Hematology, Transfusion and Cell Therapy, Vol 44, Iss , Pp S44- (2022)
Publication Year :
2022
Publisher :
Elsevier, 2022.

Abstract

Case report In Langerhans cell histiocytosis thyroid involvement is rarely seen. Here, we would like to present a 12-year-old male patient with lung, external auditory canal skin and lymph node involvement in diagnosis. Disease relapse occurred with thyroid involvement 19 months after remission. In molecular analysis, BRAF p.N 486 _P490del was detected and he reccived MEK inhibitor Trametinib monotherapy. He is still in remission for 16 months.

Details

Language :
English
ISSN :
25311379
Volume :
44
Issue :
S44-
Database :
Directory of Open Access Journals
Journal :
Hematology, Transfusion and Cell Therapy
Publication Type :
Academic Journal
Accession number :
edsdoj.61a93f3c62a643b2a9a8dc26bd2f494f
Document Type :
article
Full Text :
https://doi.org/10.1016/j.htct.2022.09.1273